Journal: Journal of pharmaceutical and biomedical analysis

Article Title: Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxifermin.

doi: 10.1016/j.jpba.2023.115402

Figure Lengend Snippet: Fig. 3. Flow chart of workflow for generation, purification, and conjugation of affinity purified chicken anti-EFXcore polyclonal antiserum.

Article Snippet: Following transfer to a nitrocellulose membrane, a polyclonal goat anti-human β-klotho antibody (R&D systems, cat # AF5889) was used, followed by an HRP-tagged rabbit anti-goat IgG secondary antibody (Invitrogen, cat. # 81–1620). β-actin was probed with a polyclonal rabbit anti-human β-actin primary antibody (Invitrogen, cat # PAI-183) followed by an HRP-tagged goat anti-rabbit IgG secondary antibody (Invitrogen, cat. # 31460).

Techniques: Purification, Conjugation Assay, Affinity Purification

Journal: EBioMedicine

Article Title: A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

doi: 10.1016/j.ebiom.2020.103202

Figure Lengend Snippet: Summary of the kinetic and affinity constants (KD) for the interaction between FGF21 mutants and β-Klotho using streptavidin (SA) biosensors.

Article Snippet: Rabbit Anti-Human β-Klotho monoclonal antibody (R&D Systems, Cat #MAB58891) or isotype control antibody (R&D Systems, Cat # AB-105-C), and anti-Rabbit IgG (PE) secondary antibody (R&D Systems, Cat # F0110) were used for β-Klotho expression.

Techniques:

Journal: EBioMedicine

Article Title: A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

doi: 10.1016/j.ebiom.2020.103202

Figure Lengend Snippet: Dual target GLP-1-Fc-FGF21 D1 functions through both GLP-1R and FGF21R/β-Klotho pathways. GLP-1-Fc-FGF21 D1, Fc-FGF21 S1 and Dulaglutide were investigated in cell based assays for their trans-activating activity. (a) ERK phosphorylation was measured in HEK293 cells expressing β-Klotho treated with native FGF21, GLP-1-Fc-FGF21 D1, Fc-FGF21 S1 or Dulaglutide. (b) cAMP secreted from HEK93 cells expressing GLP-1R treated with GLP-1-Fc-FGF21 D1, Fc-FGF21 S1 or dulaglutide. (c) HEK93 cells expressing GLP-1R and β-Klotho were treated with GLP-1-Fc-FGF21 D1, Fc-FGF21 S1, Dulaglutide or a 1:1 mixture of Fc-FGF21 S1 and Dulaglutide and the secreted cAMP were measured. (d) ERK phosphorylation was measured in HEK293 cells expressing GLP-1R and β-Klotho treated with GLP-1-Fc-FGF21 D1, Fc-FGF21 S1, Dulaglutide or a 1:1 mixture of Fc-FGF21 S1 and Dulaglutide. Data are showed as mean +/- standard errors of means, n =3.

Article Snippet: Rabbit Anti-Human β-Klotho monoclonal antibody (R&D Systems, Cat #MAB58891) or isotype control antibody (R&D Systems, Cat # AB-105-C), and anti-Rabbit IgG (PE) secondary antibody (R&D Systems, Cat # F0110) were used for β-Klotho expression.

Techniques: Activity Assay, Phospho-proteomics, Expressing